Back to Journals » ClinicoEconomics and Outcomes Research » Volume 7

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir

Authors Walker DR, Juday TR, Manthena SR, Jing Y, Sood V

Received 24 April 2015

Accepted for publication 21 September 2015

Published 17 December 2015 Volume 2015:7 Pages 637—642

DOI https://doi.org/10.2147/CEOR.S87261

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Giorgio Colombo

Video abstract presented by Mr Vipan Sood.

Views: 261

David R Walker, Timothy R Juday, Shivaji R Manthena, Yonghua Jing, Vipan Sood

Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA


Background: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is currently unknown whether adding ribavirin (RBV) to SOF + SIM, which raises the pill count from two up to eight pills a day, impacts adherence. The aim of this study is to examine the impact of pill count on real-world adherence rates in patients treated with SOF + SIM with and without RBV.
Methods: This retrospective study assessed composite adherence to SOF and SIM over 12 weeks of treatment for two cohorts of hepatitis C patients: one initiating SOF + SIM therapy, and the other initiating SOF + SIM + RBV therapy. Analyses were conducted using MarketScan® and Optum US commercial pharmacy claims and enrollment data. Adherence was adjusted by treatment regimen, age, sex, co-pay, presence/absence of cirrhosis, treatment history, and Charlson Comorbidity Index.
Results: There was a significant difference in composite unadjusted and adjusted adherence rates for SOF and SIM for the SOF + SIM vs SOF + SIM + RBV cohorts based on MarketScan data (unadjusted, 92.6% and 89.7%, respectively; P=0.0423; adjusted, 92.2% and 88.7%, respectively; P=0.0176), but not based on Optum data (unadjusted, 94.8% and 95.6%, respectively; P=0.5618; adjusted, 94.8% and 95.1%, respectively; P=0.8589). In the MarketScan and Optum databases, there were no statistical differences in unadjusted and adjusted adherence rates for SOF. Unadjusted and adjusted adherence rates for SIM were mixed, as they were for composite adherence.
Conclusion: The impact of the addition of RBV to SOF + SIM therapy was mixed. The impact of RBV on SOF adherence was not significant in either database.

Keywords: adherence, hepatitis C, direct acting antiviral, sofosbuvir, simeprevir, ribavirin

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms

Ramakrishnan K, Bond TC, Claxton A, Sood VC, Kootsikas M, Agnese W, Sibbel S

International Journal of Nephrology and Renovascular Disease 2014, 7:1-12

Published Date: 19 December 2013

High burden and unmet patient needs in chronic kidney disease

Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C

International Journal of Nephrology and Renovascular Disease 2012, 5:151-163

Published Date: 13 December 2012

Readers of this article also read:

Microcurrent stimulation in the treatment of dry and wet macular degeneration

Chaikin L, Kashiwa K, Bennet M, Papastergiou G, Gregory W

Clinical Ophthalmology 2015, 9:2345-2353

Published Date: 17 December 2015

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration

Balaratnasingam C, Dhrami-Gavazi E, McCann JT, Ghadiali Q, Freund KB

Clinical Ophthalmology 2015, 9:2355-2371

Published Date: 17 December 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010